The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients

This study has been completed.
Information provided by:
CHU de Charleroi Identifier:
First received: July 24, 2006
Last updated: November 30, 2006
Last verified: October 2000

To examine the effects of the addition of clonidine to diuretics on the mobilization of ascites at short-term (diuretic response and requirement of diuretics) and long-term (readmissions for tense ascites and requirement of diuretics) in cirrhotics with increased sympathetic nervous system. Secondary objectives were to study neuro-hormonal,hemodynamic effects and side effects of clonidine and diuretics.

Condition Intervention
Ascitic Cirrhosis
Hyperactivation of Sympathetic Nervous System
Drug: clonidine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.

Resource links provided by NLM:

Further study details as provided by CHU de Charleroi:

Estimated Enrollment: 64
Study Start Date: October 2000

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cirrhotic patients with ascites
  • Plasma norepinephrine level > 300 pg/mL (normal value: 185 – 275 pg/mL)

Exclusion Criteria:

  • Serum bilirubin concentration above 4.5 mg/dL
  • Prothrombin time below 40%
  • Platelet count below 40 X 10¨9/liter
  • Serum creatinine concentration above 2 mg/dL
  • Gastro-intestinal hemorrhage
  • Alcoholic hepatitis
  • Diabetes mellitus,
  • Hepatocellular carcinoma
  • Respiratory or cardiac failures
  • Hepatic encephalopathy
  • Bacterial infection
  Contacts and Locations
Please refer to this study by its identifier: NCT00356226

ISPPC CHU de Charleroi
Charleroi, Belgium, 6000
Sponsors and Collaborators
CHU de Charleroi
Principal Investigator: Lenaerts Anne, MD ISPPC CHU de Charleroi
  More Information

Publications: Identifier: NCT00356226     History of Changes
Other Study ID Numbers: HEP-05-1550.R2
Study First Received: July 24, 2006
Last Updated: November 30, 2006
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment

Keywords provided by CHU de Charleroi:

Additional relevant MeSH terms:
Liver Cirrhosis
Liver Diseases
Digestive System Diseases
Pathologic Processes
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Sensory System Agents
Central Nervous System Agents
Natriuretic Agents processed this record on April 17, 2014